11/14
08:22 am
lgnd
Ligand to Present at Stifel 2024 Healthcare Conference [Yahoo! Finance]
Medium
Report
Ligand to Present at Stifel 2024 Healthcare Conference [Yahoo! Finance]
11/14
08:00 am
lgnd
Ligand to Present at Stifel 2024 Healthcare Conference
Medium
Report
Ligand to Present at Stifel 2024 Healthcare Conference
11/12
09:44 pm
lgnd
iMetabolic Biopharma Receives Second NIH Grant Award for Drug Discovery [Yahoo! Finance]
Low
Report
iMetabolic Biopharma Receives Second NIH Grant Award for Drug Discovery [Yahoo! Finance]
11/12
09:43 am
lgnd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Royal Bank of Canada from $130.00 to $140.00. They now have an "outperform" rating on the stock.
Low
Report
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Royal Bank of Canada from $130.00 to $140.00. They now have an "outperform" rating on the stock.
11/8
03:34 pm
lgnd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Benchmark Co. from $110.00 to $135.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Benchmark Co. from $110.00 to $135.00. They now have a "buy" rating on the stock.
11/8
01:44 pm
lgnd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Barclays PLC from $125.00 to $150.00. They now have an "overweight" rating on the stock.
Low
Report
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Barclays PLC from $125.00 to $150.00. They now have an "overweight" rating on the stock.
11/8
11:17 am
lgnd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Oppenheimer Holdings Inc. from $135.00 to $147.00. They now have an "outperform" rating on the stock.
Low
Report
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Oppenheimer Holdings Inc. from $135.00 to $147.00. They now have an "outperform" rating on the stock.
11/8
08:46 am
lgnd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $157.00 price target on the stock.
Low
Report
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $157.00 price target on the stock.
11/8
07:43 am
lgnd
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price [Yahoo! Finance]
Medium
Report
Ligand Pharmaceuticals Incorporated's (NASDAQ:LGND) Intrinsic Value Is Potentially 99% Above Its Share Price [Yahoo! Finance]
11/8
02:21 am
lgnd
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
Medium
Report
Ligand Pharmaceuticals Inc (LGND) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ... [Yahoo! Finance]
11/7
07:00 am
lgnd
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
High
Report
Ligand Reports Third Quarter 2024 Financial Results and Raises 2024 Guidance
11/6
07:21 am
lgnd
Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
Medium
Report
Ligand Pharmaceuticals Inc (LGND) Q3 2024: Everything You Need To Know Ahead Of Earnings [Yahoo! Finance]
11/1
08:05 am
lgnd
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston [Yahoo! Finance]
Medium
Report
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston [Yahoo! Finance]
11/1
08:01 am
lgnd
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
Medium
Report
Ligand to Host Investor and Analyst Day on December 10, 2024 in Boston
10/31
10:42 am
lgnd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $157.00 price target on the stock.
Low
Report
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $157.00 price target on the stock.
10/28
10:11 am
lgnd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Barclays PLC from $110.00 to $125.00. They now have an "overweight" rating on the stock.
Low
Report
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at Barclays PLC from $110.00 to $125.00. They now have an "overweight" rating on the stock.
10/23
04:01 pm
lgnd
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
Medium
Report
Ligand to Report Third Quarter 2024 Financial Results on November 7, 2024
10/21
08:07 am
lgnd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at HC Wainwright from $144.00 to $157.00. They now have a "buy" rating on the stock.
Low
Report
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) had its price target raised by analysts at HC Wainwright from $144.00 to $157.00. They now have a "buy" rating on the stock.
10/4
06:23 am
lgnd
Palvella secures FDA grant for Phase III microcystic LMs treatment trial [Yahoo! Finance]
Low
Report
Palvella secures FDA grant for Phase III microcystic LMs treatment trial [Yahoo! Finance]
10/3
11:53 am
lgnd
Ligand started at outperform by Oppenheimer on royalty revenue growth [Seeking Alpha]
Low
Report
Ligand started at outperform by Oppenheimer on royalty revenue growth [Seeking Alpha]
10/3
08:17 am
lgnd
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $135.00 price target on the stock.
Low
Report
Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $135.00 price target on the stock.
9/25
08:02 am
lgnd
Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? [Yahoo! Finance]
Low
Report
Can Mixed Fundamentals Have A Negative Impact on Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) Current Share Price Momentum? [Yahoo! Finance]
9/6
09:23 am
lgnd
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy [Yahoo! Finance]
Medium
Report
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy [Yahoo! Finance]
9/6
09:20 am
lgnd
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
Medium
Report
Ligand Partner Travere Therapeutics Receives Full FDA Approval for FILSPARI® (sparsentan), the Only Non-Immunosuppressive Treatment that Significantly Slows Kidney Function Decline in IgA Nephropathy
9/6
07:36 am
lgnd
Travere gains on full FDA approval for kidney drug Filspari [Seeking Alpha]
Low
Report
Travere gains on full FDA approval for kidney drug Filspari [Seeking Alpha]